Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab

  • J. A. Bonner
    University of Alabama, Birmingham, AL; University of Wisconsin, Madison, WI; Vall D'Hebron University Hospital, Barcelona, Spain; ImClone Systems, Somerville, NJ; University of Virginia, Charlottesville, VA; University of Colorado, Aurora, CO; Sutter Cancer Center, Sacramento, CA; UT MD Anderson Cancer Center, Houston, TX
  • P. M. Harari
    University of Alabama, Birmingham, AL; University of Wisconsin, Madison, WI; Vall D'Hebron University Hospital, Barcelona, Spain; ImClone Systems, Somerville, NJ; University of Virginia, Charlottesville, VA; University of Colorado, Aurora, CO; Sutter Cancer Center, Sacramento, CA; UT MD Anderson Cancer Center, Houston, TX
  • J. Giralt
    University of Alabama, Birmingham, AL; University of Wisconsin, Madison, WI; Vall D'Hebron University Hospital, Barcelona, Spain; ImClone Systems, Somerville, NJ; University of Virginia, Charlottesville, VA; University of Colorado, Aurora, CO; Sutter Cancer Center, Sacramento, CA; UT MD Anderson Cancer Center, Houston, TX
  • N. Azarnia
    University of Alabama, Birmingham, AL; University of Wisconsin, Madison, WI; Vall D'Hebron University Hospital, Barcelona, Spain; ImClone Systems, Somerville, NJ; University of Virginia, Charlottesville, VA; University of Colorado, Aurora, CO; Sutter Cancer Center, Sacramento, CA; UT MD Anderson Cancer Center, Houston, TX
  • R. B. Cohen
    University of Alabama, Birmingham, AL; University of Wisconsin, Madison, WI; Vall D'Hebron University Hospital, Barcelona, Spain; ImClone Systems, Somerville, NJ; University of Virginia, Charlottesville, VA; University of Colorado, Aurora, CO; Sutter Cancer Center, Sacramento, CA; UT MD Anderson Cancer Center, Houston, TX
  • D. Raben
    University of Alabama, Birmingham, AL; University of Wisconsin, Madison, WI; Vall D'Hebron University Hospital, Barcelona, Spain; ImClone Systems, Somerville, NJ; University of Virginia, Charlottesville, VA; University of Colorado, Aurora, CO; Sutter Cancer Center, Sacramento, CA; UT MD Anderson Cancer Center, Houston, TX
  • C. Jones
    University of Alabama, Birmingham, AL; University of Wisconsin, Madison, WI; Vall D'Hebron University Hospital, Barcelona, Spain; ImClone Systems, Somerville, NJ; University of Virginia, Charlottesville, VA; University of Colorado, Aurora, CO; Sutter Cancer Center, Sacramento, CA; UT MD Anderson Cancer Center, Houston, TX
  • M. S. Kies
    University of Alabama, Birmingham, AL; University of Wisconsin, Madison, WI; Vall D'Hebron University Hospital, Barcelona, Spain; ImClone Systems, Somerville, NJ; University of Virginia, Charlottesville, VA; University of Colorado, Aurora, CO; Sutter Cancer Center, Sacramento, CA; UT MD Anderson Cancer Center, Houston, TX
  • J. Baselga
    University of Alabama, Birmingham, AL; University of Wisconsin, Madison, WI; Vall D'Hebron University Hospital, Barcelona, Spain; ImClone Systems, Somerville, NJ; University of Virginia, Charlottesville, VA; University of Colorado, Aurora, CO; Sutter Cancer Center, Sacramento, CA; UT MD Anderson Cancer Center, Houston, TX
  • K. K. Ang
    University of Alabama, Birmingham, AL; University of Wisconsin, Madison, WI; Vall D'Hebron University Hospital, Barcelona, Spain; ImClone Systems, Somerville, NJ; University of Virginia, Charlottesville, VA; University of Colorado, Aurora, CO; Sutter Cancer Center, Sacramento, CA; UT MD Anderson Cancer Center, Houston, TX

収録刊行物

  • Journal of Clinical Oncology

    Journal of Clinical Oncology 22 (14_suppl), 5507-5507, 2004-07-15

    American Society of Clinical Oncology (ASCO)

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ